Ottobock vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ottobock is the world's leading prosthetics and orthotics manufacturer with 100+ years of history; IPO'd on Frankfurt Stock Exchange (OBCK.F) in Oct 2025 at €4.2B valuation; 9,300 employees across 45 countries.
About
Ottobock is a German medical technology company and the world''s market leader in prosthetics, with a dominant position in orthotics, neuro-orthotics, exoskeletons, and mobility solutions including wheelchairs. Founded in 1919 and headquartered in Duderstadt, Germany, Ottobock has over a century of innovation history — including pioneering myoelectric prosthetic arms, microprocessor-controlled knees, and bionically enhanced limb systems. The company serves people with physical disabilities and limb loss globally through a combination of clinical care, device manufacturing, and healthcare professional training.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.